Renovaro BioSciences (NASDAQ: RENB), a biotechnology corporation focusing on cell, gene and immunotherapy, has announced the results of its special meeting of shareholders (“special meeting”) held at 12:00 p.m. ET on Jan. 25, 2024. According to the announcement, all matters put forward before the company’s shareholders for consideration and approval, as set out in Renovaro’s definitive proxy statement dated Jan. 3, 2024, were approved by the requisite number of votes cast at the meeting. For complete results on all matters voted on at the special meeting, review the company’s Form 8-K, which will be filed on EDGAR.
To view the full press release, visit https://ibn.fm/UyWHG
About Renovaro BioSciences Inc.
Renovaro has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information on Renovaro, visit the company’s website at www.Renovarobio.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]